US Patent

US7504095 — Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency

Method of Use · Assigned to Technische Universitaet Braunschweig · Expires 2029-04-09 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for obtaining a precursor called Z, used in the production of a therapy for human molybdenum cofactor deficiency.

USPTO Abstract

The invention relates to a method for obtaining the molybdopterin derivative precursor Z, wherein an over-production of precursor Z occurs in host organisms by recombinant expression of precursor Z synthesizing proteins. The invention further relates to the use of precursor Z for the production of a means for the therapy of human molybdenum cofactor deficiency and associated diseases, which may be directly or indirectly attributed to an altered molybdenum cofactor synthesis, whereby precursor Z is used as essential component of said therapy means.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3092 fosdenopterin-hydrobromide

Patent Metadata

Patent number
US7504095
Jurisdiction
US
Classification
Method of Use
Expires
2029-04-09
Drug substance claim
No
Drug product claim
Yes
Assignee
Technische Universitaet Braunschweig
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.